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Introduction
Over the past decades, major advances were made 
in the field of HIV-1 care, but a curative strategy is still 
out of reach due to the presence of persistent cellular 
viral reservoirs which are spread across different ana-
tomical compartments in the human body and cause 
viral rebound after therapy cessation. Despite the fact 
that early treatment initiation can limit the size of these 
HIV-1 reservoirs, it cannot prevent its establishment 
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during the early days of infection or revoke its latent 
state. Hence, an additional intervention targeting these 
reservoirs will be mandatory to achieve a cure1.
An HIV-1 reservoir is defined as any infected cell popu-
lation where HIV-1 persists as integrated provirus despite 
optimal combined antiretroviral therapy (cART)2. These 
infected cells are present in the peripheral blood and main-
ly consist of resting memory CD4+ T-cells. Other ana-
tomical compartments are suggested to harbor latently 
infected cells such as lymphoid tissue spread throughout 
the body3, the gastrointestinal tract, and the central ner-
vous system2,4. The latent HIV-1 reservoir can be defined 
as that part of the HIV-1 reservoir that harbors replication-
competent proviruses which can produce new infectious 
particles and infect other cells once treatment is inter-
rupted and the latent state of the cells is reversed4. Hence, 
to achieve an HIV-1 cure, these different reservoirs and 
compartments need to be studied in depth to identify their 
respective clinical significance and to unravel the mecha-
nisms by which latency is established or maintained5,6.
There are different ways to investigate the viral reser-
voir in HIV-1-infected individuals and although viral load 
measurements are the gold standard in follow-up of 
chronically infected HIV-1 patients to assess viral control 
and therapy compliance, once the patient is virologi-
cally suppressed, it cannot longer provide information 
on the HIV-1 reservoir. Therefore, other, more sensitive 
assays, are used to quantitatively and qualitatively mea-
sure the HIV-1 reservoir such as polymerase chain re-
action (PCR)-based methods (e.g.,  quantitative or 
digital PCR), cell-culture-based methods (e.g. viral out-
growth assays), immunophenotyping techniques and 
several sequencing approached developed for HIV-1 
full-length and integration site investigation5.
In this systematic review, we assessed how the study 
of anatomical compartments has evolved over time in 
the context of HIV-1 reservoir studies, especially in 
terms of compartment sampling, study participants, 
study design and research techniques.
Materials and methods
Systematic literature screening
We performed a systematic literature search on HIV-
1 reservoir studies using the online databases PubMed 
(www.ncbi.nlm.nih.gov/pubmed), Web of Science 
(www.webofknowledge.com), and clinicaltrials.gov for 
the time period 1987-2019 (Fig. 1).
The following search terms were used in PubMed and 
Web of Science to construct the initial dataset of articles: 
“HIV-1 reservoir lymph node”, “HIV-1 reservoir lung”, “HIV-
1 reservoir gut”, “HIV-1 reservoir bone marrow”, “HIV-1 
reservoir rectal tissue”, “HIV-1 reservoir gut-associated 
lymphoid tissue (GALT)”, “HIV-1 reservoir brain”, “HIV-1 
reservoir central nervous system”, and “total body HIV-1 
reservoir”. In addition, the term HIV-1 reservoir was also 
searched for in clinical trials related to HIV-1 interventional 
and observational studies with published articles (on clin-
icaltrials.gov). Here, advanced search terms included “in-
terventional studies” or “observational studies, completed”.
The total set of 1768 identified articles was pooled 
together, duplicates removed, and the first filtering was 
performed based on following exclusion criteria: review 
articles, non-English manuscripts, no full-text available 
and article publication date before 2000 without recent 
citation. Recent citation was defined as articles that were 
cited in the past 10 years (from 2010 onward). The re-
maining set of articles were manually evaluated based 
on their abstract with the following exclusion criteria: in 
vitro studies, studies on animals including primates, only 
peripheral blood mononuclear cells included, no relevant 
reservoirs, non-HIV-1 and studies focusing on autopsies.
Data processing and visualization
The included articles were represented as a data matrix 
in Microsoft Excel (2016) (Supplemental  Table 1-3). These 
tables include information on the number of patients in-
cluded and their main characteristics, the number of com-
partments that were studied and which compartments 
and research techniques that were applied to investigate 
these compartments. In terms of possible HIV-1 compart-
ments, we especially focused on blood, lymph nodes, bone 
marrow, central nervous system, lungs and the gastrointes-
tinal tract. In addition, the research techniques were grouped 
in four categories: PCR-based quantification, non-PCR-
based quantification, immunophenotyping and qualitative 
sequencing approaches (Supplemental Table 4).
The graphs summarizing the data from these articles 
were made in R (v.3.4.0) using RStudio (v1.0.143) and 
the ggplot2 package (v2.2.1). Trends were made visual 
by implementing non-parametric moving regression 
analysis with Locally Weighted Scatterplot Smoothing.
Results
HIV-1 reservoir studies: systematic 
literature search
The systematic literature screening resulted in the 
inclusion of 106 HIV-1 reservoir studies over the time 
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period 1987 to present, with an observed increase in 
the amount of studies between 2010 and 2018 which 
underlines the efforts made in HIV-1 reservoir research 
to better understand the latent reservoir and work to-
ward a cure (Fig. 2a).
Anatomical compartments
In total, 229 samples from five different compartments 
were reported across 106 reservoir studies with an in-
creasing number of compartments sampled per study 
Figure 1. Systematic literature screening pipeline. Overview of the stepwise approach used to identify the set of 106 HIV-1 reservoir stud-
ies in the time period 1987-2019.
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over time (Fig. 2b and c). Since 2010, reservoir studies 
include two or more compartments and even sample up 
to five different compartments in a single study.
Overall, gut (55 studies) and lymph node (30 studies) 
tissues were sampled the most besides the blood com-
partment which was sampled in 103 out of 106 studies 
(Fig. 3a-c). However, when investigating the compart-
ment sampling over time, there is an observed in-
crease in cerebrospinal fluid (CSF) and lymph node 
sampling together with a decreased sampling of gut 
tissues in recent years (Fig. 3b-d). Interest in bone 
marrow (BM) has declined over the years and the 
amount of studies including lung sampling has been 
low (Fig. 3e and f).
Longitudinal sampling and patient 
inclusion
Although the majority of studies still focus on a single 
cross-sectional time point (66 vs. 40 studies), longitu-
dinal sampling at multiple (> 1) time points increased 
over the recent years, reaching 40% of total HIV-1 
reservoir studies (Fig. 4a and b).
Zooming in on ART status of patients enrolled, 38% of 
the reservoir studies included patients on and off thera-
py, 45% of the studies included only patients on ART, 
and 16% only included patients off ART. In addition, 
there is a stable inclusion of healthy volunteers over time, 
reaching on average 20% of reservoir studies published.
When combining longitudinal sampling and ART sta-
tus, studies that consider one time point focus more on 
controlled aviremic participants that are on ART 
(Fig. 4c).
Research methods
When dissecting the research methods used to study 
the viral reservoir, we observe that in 77% of the stud-
ies, PCR-based techniques are used, 48% non-PCR 
based, 35% immunophenotyping and 25% qualitative 
analysis. Since 2000, there has been an increase in 
qualitative analyses as well as a continuous increase 
in the implementation of immunophenotyping tech-
niques (Fig. 5a-d). Although 65% of studies perform 
subset sorting, there is an increase in usage of bulk 
cells around the 2000 (Fig. 5e and f).
Discussion
Where the initial goal of HIV-1 research was to un-
derstand the natural course of disease and the effect 
of cART on virus and host, the focus has now shifted 
toward identifying the drivers of viral persistence in HIV-
1-infected patients and tackle the last hurdle toward a 
cure, namely, the latent HIV-1 reservoir. By conducting 
this systematic review, we identified three shifts in res-
ervoir studies that merit attention.
Importance of multiple tissues and 
compartment sampling
Although immune cells isolated from peripheral blood 
have been extensively studied due to their easy access, 
the importance of viral sanctuaries in peripheral tissues 
has gained research attention over the past years. In 
this review, we especially focused on lymph nodes, 
Figure 2. Evolution of HIV-1 reservoir studies. A: The absolute number of HIV-1 reservoir studies is plotted per year for the time period 
1987-2019. The Locally Weighted Scatterplot Smoothing regression line is added in blue; B: The number of reservoir studies including one 
of the following compartments: blood, lymph node, lung bronchoalveolar lavage, bone marrow, cerebrospinal fluid, or gut; C: Evolution of 
the average number of compartments included in reservoir studies over the time period 1987-2019. The Lowess regression line is added 
in blue.
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bone marrow, the central nervous system, the lungs, 
and the gastrointestinal tract as possible HIV-1 com-
partments.
Lymph nodes and lymphoid tissue are important 
sites for viral production, storage, and persistence2,4. 
The frequency of infections per cell is mostly higher in 
here than in immune cells in the blood7. Previous stud-
ies have shown that the intracellular drug concentration 
is lower in here, compared to in the blood, which can 
explain why it is a site of viral persistence2,8. Further-
more, lymph nodes play a key role as primary defense 
organ after infection9. Cells from the site of infection 
migrate to the lymph node and cause a very early site 
of HIV-1 infection10,11. Therefore, this reservoir remains 
of very high interest, although sampling is challenging.
The gastrointestinal tract is known to sequester the 
majority of lymphocytes and the GALT is a major 
viral reservoir in HIV-1  patients3,12. These lympho-
cytes are depleted early after primary infection2 and 
do not return to their normal levels despite long-term 
cART13. A possible mechanism underlying HIV-1 per-
sistence in this compartment may be the continuous 
Figure  3. Evolution in the study of individual anatomic compartments in HIV-1 reservoir studies. For each compartment, the fraction of 
studies including the compartment of interest is plotted over the time period 1987-2019: A: blood; B: gut; C: lymph node; D: cerebrospinal 
fluid; E: bone marrow; and F: lung (bronchoalveolar lavage). The Locally Weighted Scatterplot Smoothing regression line is added in blue.
A B C
D E F
Figure 4. Longitudinal sampling in HIV-1 reservoir studies. A: the number of reservoir studies which include single (red) or multiple (blue) 
time points in three time periods: 1987-1999, 2000-2009, and 2010-2019; B: fraction of reservoir studies including single (red) or multiple 
(blue) time points over the time period 1987-2019 with respective Locally Weighted Scatterplot Smoothing regression line; C: the number 
of studies with patients on antiretroviral therapy which include multiple or single time points.
A B C
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immune activation caused by antigenic stimulation 
of resting B-  and T-cells, increasing their turnover 
providing a constant source of susceptible cells13. 
When comparing compartments, the GALT is the 
most studied compartment besides the blood in ab-
solute numbers. Indeed, the gut harbors possibly the 
biggest HIV-1 reservoir in the body, this in combina-
tion with being accessible for biopsies explains the 
broad interest for this reservoir2,3,12. However, we 
see a decline in the fraction of studies including the 
GALT in the past few years, potentially due to the 
low amount of immune cells recovered, limiting the 
types of analysis that can be conducted. Moreover, 
it is important to acknowledge differences between 
immune cells and gene expression between different 
regions of the colon, requiring a total colonoscopy 
for ileal biopsy compared to the left colon (sigmoid) 
biopsies14.
Various cells can be infected within the brain, most-
ly from the monocyte lineage2. This reservoir is clini-
cally relevant because patients can develop neuro-
logical complications such as HIV-1-associated 
dementia when the control of HIV-1 is not sufficient15. 
Although HIV-1-associated dementia is rare when pa-
tients are treated with cART2, mild neurocognitive im-
pairment is commonly observed despite suppressive 
cART. In this light, the CSF has been proposed as a 
viral sanctuary; however, the relevance in HIV-1 la-
tency is unclear and the role in HIV-1 viral rebound 
after treatment interruption is doubtful16,17. It is, there-
fore, mostly studied as a sanctuary site, evolving sep-
arately from the other compartments11,16.
In the lungs, it has been shown that HIV-1 infection 
worsens alveolar macrophage immune functions and in 
this way, it makes patients more susceptible to bacte-
rial and viral infections18. These macrophages are the 
major viral reservoir in the lungs13. However, their rel-
evance in latency is unclear and seems to be minor4. 
Finally, although studies have been investigating the 
role of CD34+ hematopoietic precursor cells, there is no 
clear answer to date whether these cells contain latent 
virus19,20. With caution, we can suggest that the major 
source of virus in the bone marrow is likely to be found 
in migratory CD4+ T-cells from the peripheral blood4. 
Lung and bone marrow biopsies lost interest over the 
years, as they appear to be less relevant, with a poor 
access to biopsies and low cell yields of the samples, 
not allowing for thorough downstream analysis4,19,21.
Figure 5. The evolution of research methods and techniques used in HIV-1 reservoir studies. The fraction of reservoir studies including one 
of the following research method categories A: qualitative techniques; B: polymerase chain reaction (PCR)-based quantification; C: im-
munophenotyping or D: non-PCR-based quantification. The fraction of reservoir studies including bulk cells (E) or subset sorting (F) in the 
time period 1987-2019.
A B C
D E F
AIDS Reviews. 2020;22
22
We can conclude that there is a clear consensus 
about the relevance of the lymphoid tissue as an im-
portant HIV-1 reservoir. Overall, we see that the study 
setup and techniques have been adapted to answer 
to these reservoir challenges and mostly to have a 
better study of the involved reservoirs.
Increased uniformity in patient inclusion 
and longitudinal sampling
Over time, there is an increased uniformity in the 
study population and time points of sampling due to 
the urge to better understand the kinetics and dynam-
ics of the HIV-1 reservoir. This is most evident in the 
studies sampling one time point with almost all of these 
studies including virologically suppressed patients on 
cART. The reason for this is mainly to limit bias caused 
by comorbidities, coinfection, ongoing disease, and 
AIDS-related illnesses2,13,22. Recent studies further 
limit heterogeneity by focusing, for example, on very 
early treated patients4,6,23. The same evolution is seen 
in studies that sample on multiple time points, they 
mostly compare patients on and off cART. In this way, 
they can study the effect of treatment initiation or eval-
uate an intervention by analytical treatment interruption 
(ATI)24-26.
Although sampling at different time points offers the 
opportunity that the patient is his own control, this 
multiple sampling is also very demanding for the pa-
tients and, therefore, not always feasible.
Importance of multiple research methods 
to assess size and quality of HIV-1 
reservoirs
With the shift toward the assessment of the quality of 
the HIV-1 reservoir in the context of disease relapse 
after ATI and the role in immune activation during 
cART, we observe a trend toward a more combined 
approach including quantitative and qualitative mea-
surements. PCR-based techniques allow us to quantify 
total HIV-1 DNA, integrated HIV-1 DNA, 2 LTR circles, 
spliced RNA, and cell-associated (CA) RNA and pro-
vide very important information on the size of the res-
ervoir in patients, informing on the viral burden, and 
total reservoir size4,27. PCR-based methods remain the 
most frequently used through the years, due to their 
high availability, relative low cost, and high through-
put6,23,28. However, these assays greatly overestimate 
the latent reservoir since they cannot distinguish be-
tween defective and intact virus23,28. The quantitative 
viral outgrowth assay is an example of a non-PCR 
based methods and is currently the gold standard to 
detect replication-competent virus29. The main disad-
vantages are its cost and the resource-intensive ap-
proach. Furthermore, this assay is not perfect in detect-
ing all replication-competent virus which can lead to 
an underestimation23,28,30. A non-PCR-based technique 
more focused toward tissues is next-generation in situ 
hybridization. These assays can detect low copy viral 
DNA and RNA signals in situ using RNA/DNA scope 
techniques and have been a major advance in the 
study of these tissues28,31,32. Many variations exist both 
for PCR and non-PCR-based quantitative techniques, 
all focusing on other demands, being more sensitive, 
quicker, measuring immune responses, or being less 
expensive, with the PCR-based assays being the most 
flexible23,30. Recent advances in sequencing have 
changed the field of HIV research once more. Qualita-
tive measurements rise in use after 2000. This is in line 
with the shift from measuring the amount of HIV-1 pres-
ent, to analyzing the HIV-1 reservoirs and their respec-
tive relevance in HIV-1 persistence and viral rebound30. 
Single genome and proviral sequencing is a technique 
which analyses HIV-1 DNA and RNA down to a single 
copy. A great advantage of single genome sequencing 
is that the genetic composition of the viral DNA and 
RNA can be unraveled. In this way, genetic changes 
between anatomic compartments and cell types can 
be measured and viral rebound can be linked to these 
sites. A  disadvantage of this technique is that until 
recently, we were only able to sequence small parts of 
the virus. A possible solution for this problem is near 
full-length sequencing assays, able to sequence more 
than 90% of the virus, allowing for a more in-depth 
analysis of the viral genome30. Another approach is to 
sequence the integration site of the virus in the human 
genome, providing us with more information on the 
interplay between virus and host33. Due to this wide 
variation of results based on over- and underestimation 
of the functional reservoir, a combination of different 
techniques, preferentially both quantitative and qualita-
tive, should be proposed to produce a confident esti-
mate of the HIV-1 reservoir5,23.
Although all these novel techniques are promising, it 
is important to adjust the compartments, research 
techniques, and time points of sampling according to 
the research question, taking into account various 
limitations due to sampling issues or discordance be-
tween the availability and the high input needed for 
some of the techniques.
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Implications for future research
This systematic research clearly shows how advanc-
es made in cure research are correlated with a shift in 
the way clinically oriented research is conducted. The 
study interest and design have evolved, especially in 
the past 10 years. This corresponds to a shift in inter-
est toward a complete understanding of the HIV-1 res-
ervoir after viral control with cART became a reality and 
research moved on toward finding a cure for HIV-1. 
Indeed, the lessons learned from performing this sys-
tematic review were implemented in our recently pub-
lished HIV-1 reservoir study and included the following 
key features34. We started from a homogeneous study 
population, employing strict inclusion criteria to avoid 
as much as possible bias related to interparticipant 
variability. Therefore, virological, immunological, and 
treatment inclusion criteria were applied. Participants 
were sampled on and off cART, to better understand 
the mechanisms and origin of in vivo viral rebound 
when stopping cART. In-depth sampling was done 
while on cART and single genome sequencing was 
applied to analyze the phylogenetic relationships be-
tween the viruses from different cell subsets and plas-
ma rebound virus. We focused on blood, lymphoid 
tissue and gut samples as these reservoirs gave us the 
highest potential of (a) being able to collect enough 
sample to apply sequencing techniques and (b) pro-
viding answers to our research question as former 
research was convincing about their important contri-
bution to the HIV-1 reservoir. As expected, further 
analysis of bronchoalveolar lavage, CSF, BM, and 
genital samples was not contributive to our analysis 
due to the poor amount of viral sequences that could 
be obtained. When we look at the evolution in the cur-
rent research, we see a relapse in studies focusing on 
these compartments for the specific reasons men-
tioned above.
Although extensive sampling studies are very infor-
mative and needed to move toward an HIV-1 cure, 
there are several limitations that need to be consid-
ered. As formerly addressed, the availability and in-
put of sample needed to conduct different assays 
requires a strict selection beforehand in how resourc-
es are used. Furthermore, applying different se-
quencing techniques often comes at a high cost. 
Another important limitation is the relatively low num-
ber of participants that are routinely included in these 
studies due to their invasive nature and the ethical 
considerations that come with the extensive sampling 
and treatment interruption.
Conclusion
Based on these observations, we can conclude that 
HIV-1 reservoir and cure research are evolving toward 
a targeted research approach with the use of a vast 
array of techniques to achieve this goal. Furthermore, 
the study results underline the need to combine both 
quantitative and qualitative assays to further identify 
replication-competent and intact full-length viruses 
and to define relevant anatomical reservoirs in order 
to design targeted therapy. In this context, the whole 
body approach35 with extensive tissue sampling and 
analysis,34,36 clearly demonstrates a trend of integrat-
ed research within one study participant to get as 
much information as possible. This approach should 
help us to better understand the establishment and 
dynamics of the viral reservoir and its contribution to 
viral rebound after ATI.
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